RAPAd®

The RAPAd® method of Adenovirus construction, developed by ViraQuest Inc. scientists, has been used by other scientists around the world.

Request Quote

Confidentiality

 

Learn More

Quality Control

Plaque forming units guarantee. Non-detectable RCA.

Learn More

Turnaround Time

Sub-cloning to finished particles in about four weeks.

Learn More

Dual Expressers

Multiple transgene expression in a single virus.

Learn More

Tag Archives: Cancer

Sodium Iodide Symporter (NIS)-Mediated Radionuclide ((131)I, (188)Re) Therapy of Liver Cancer After Transcriptionally Targeted Intratumoral in Vivo NIS Gene Delivery.

Authors: Klutz K, Willhauck MJ, Wunderlich N, Zach C, Anton M, Senekowitsch-Schmidtke R, G
Citation: Hum Gene Ther. 2011 Jun 28. [

read more

MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma.

Authors: de Antonellis P, Medaglia C, Cusanelli E, Andolfo I, Liguori L, De Vita G, Carotenuto M, Bello A, Formiggini F, Galeone A, De Rosa G, Virgilio A, Scognamiglio I, Sciro M, Basso G, Schulte JH, Cinalli G, Iolascon A, Zollo M.
Citation: PLoS One. 2011;6(9):e24584.

read more

Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.

Authors: Harvey TJ, Hennig IM, Shnyder SD, Cooper PA, Ingram N, Hall GD, Selby PJ, Chester JD.
Citation: Cancer Gene Ther. 2011 Nov;18(11):773-84. doi: 10.1038/cgt.2011.43.

read more

Re-expression of the methylated EDNRB gene in oral squamous cell carcinoma attenuates cancer-induced pain.

Authors: Viet CT, Ye Y, Dang D, Lam DK, Achdjian S, Zhang J, Schmidt BL.
Citation: Pain. 2011 Oct;152(10):2323-32.

read more

A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer.

Authors: Trujillo MA, Oneal MJ, McDonough S, Qin R, Morris JC.
Citation: Gene Ther. 2010 Nov;17(11):1325-32.

read more

Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor.

Authors: Harvey TJ, Burdon D, Steele L, Ingram N, Hall GD, Selby PJ, Vile RG, Cooper PA, Shnyder SD, Chester JD.
Citation: Gene Ther. 2010 Aug;17(8):1000-10.

read more

Selective concomitant inhibition of mTORC1 and mTORC2 activity in estrogen receptor negative breast cancer cells by BN107 and oleanolic acid.

Authors: Chu R, Zhao X, Griffin C, Staub RE, Shoemaker M, Climent J, Leitman D, Cohen I, Shtivelman E, Fong S.
Citation: Int J Cancer. 2010 Sep 1;127(5):1209-19.

read more

Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer.

Authors: Trujillo MA, Oneal MJ, Davydova J, Bergert E, Yamamoto M, Morris JC 3rd.
Citation: Breast Cancer Res. 2009;11(4):R53.

read more

INSM1 promoter-driven adenoviral herpes simplex virus thymidine kinase cancer gene therapy for the treatment of primitive neuroectodermal tumors.

Authors: Wang HW, Breslin MB, Chen C, Akerstrom V, Zhong Q, Lan MS.
Citation: Hum Gene Ther. 2009 Nov;20(11):1308-18.

read more

Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression

Authors: Spitzweg C, Baker CH, Bergert ER, O'Connor MK, Morris JC
Citation: Hum Gene Ther 2007 Oct 18 10: 916-924

read more